The Australia GLP-1 receptor agonist market size is calculated at USD 570.49 million in 2025 and is forecasted to reach around USD 1,899.62 million by 2034, accelerating at a CAGR of 14.30% from 2025 to 2034. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Australia GLP-1 Receptor Agonist Industry Impact
5.2. COVID-19 - Impact Assessment for the Industry
5.3. COVID-19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Australia GLP-1 Receptor Agonist Market, by Product Type
8.1.1 Injectables
8.1.1.1. Market Revenue and Forecast
8.1.2. Oral GLP-1 Receptor Agonists
8.1.2.1. Market Revenue and Forecast
9.1. Australia GLP-1 Receptor Agonist Market, by Application
9.1.1. Type 2 Diabetes Management
9.1.1.1. Market Revenue and Forecast
9.1.2. Obesity and Weight Management
9.1.2.1. Market Revenue and Forecast
9.1.3. Cardiovascular Diseases (CV)
9.1.3.1. Market Revenue and Forecast
10.1. Australia GLP-1 Receptor Agonist Market, by End User
10.1.1. Hospitals
10.1.1.1. Market Revenue and Forecast
10.1.2. Clinics
10.1.2.1. Market Revenue and Forecast
10.1.3. Retail Pharmacies
10.1.3.1. Market Revenue and Forecast
10.1.4. Homecare/Direct-to-Patient
10.1.4.1. Market Revenue and Forecast
11.1. AstraZeneca PLC
1.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. Biocon
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. Eli Lilly and Co
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. Novo Nordisk A/S ADR
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. Recent Initiatives
11.5. Sanofi SA
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
13.1. About Us
13.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
Plan your call and get expert insights!
Schedule a Meeting
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample